Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

79.31USD
26 Aug 2016
Change (% chg)

-- (--)
Prev Close
$79.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,719,633
52-wk High
$98.97
52-wk Low
$69.89

NVS

Chart for NVS

About

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $210,234.41
Shares Outstanding(Mil.): 2,627.11
Dividend: 2.72
Yield (%): 3.43

Financials

  NVS Industry Sector
P/E (TTM): 28.68 36.93 36.63
EPS (TTM): 2.77 -- --
ROI: 6.33 14.69 14.12
ROE: 8.82 15.48 15.04

Novartis announces positive phase III results for MS drug siponimod

ZURICH, Aug 25 Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.

Aug 25 2016

Turkey's investigation into drugmaker Novartis 'ongoing': official

ISTANBUL/ZURICH Turkey's investigation into Novartis is "ongoing", a Turkish health ministry official told Reuters on Thursday, after the Swiss drugmaker said last week it was not under investigation over bribery allegations in Turkey.

Aug 17 2016

UPDATE 3-Turkey's investigation into drugmaker Novartis 'ongoing' -official

* Novartis says still sees matter as closed, making checks (Updates to show Novartis no longer seeking information from Turkey)

Aug 17 2016

BRIEF-Jacobs wins contract for Novartis Biotechnology Center expansion

* Jacobs awarded contract for Novartis Biotechnology Center expansion in France

Aug 11 2016

Valeant names new general counsel, says PR head to leave

Canadian drugmaker Valeant Pharmaceuticals International Inc on Monday named a new general counsel and announced the departure of its public relations head.

Aug 08 2016

AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes

LONDON AstraZeneca shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.

Aug 05 2016

Novartis pill gets U.S. breakthrough designation in breast cancer

ZURICH, Aug 3 Novartis AG breast cancer pill LEE011 has won breakthrough therapy designation from U.S. regulators as a first-line treatment for a form of advanced breast cancer, the Swiss drugmaker said on Wednesday.

Aug 03 2016

GSK and Google parent forge $715 million bioelectronic medicines firm

LONDON GlaxoSmithKline and Google parent Alphabet's life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.

Aug 01 2016

UPDATE 2-GSK and Google parent forge $715 mln bioelectronic medicines firm

* Uses miniaturised implants attached to individual nerves (Adds interview with executive, further details)

Aug 01 2016

BRIEF-Genvec says FDA lifts hold on clinical trial of hearing loss treatment

* Notified by Novartis that FDA has lifted clinical hold on phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 25 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $119.04 +0.47
Pfizer Inc. (PFE.N) $34.82 +0.05
Merck & Co., Inc. (MRK.N) $62.85 +0.53
Roche Holding Ltd. (ROG.S) CHF240.70 -0.20
Roche Holding Ltd. (RO.S) CHF241.00 -1.00
Abbott Laboratories (ABT.N) $42.98 +0.14
Sanofi SA (SASY.PA) €68.90 -0.45
AstraZeneca plc (AZN.L) 4,955.00p -56.00
GlaxoSmithKline plc (GSK.L) 1,649.50p -3.50
Eli Lilly and Co (LLY.N) $78.24 +0.23

Earnings vs. Estimates